Competition in Pharmaceuticals

1745 Words4 Pages
bulb-icon

Recommended: supply chain management of square pharmaceuticals

For the threat of substitute products, it is still very low due to the patents protection but in case of the expired patents, it is medium. A pharmaceutical company has lots of way to fight back against generic drugs such as obtaining patents on component chemicals, manufacturing methods, product extension/formula modifications or improving drug-delivery methods. Rivalry among existing firms is medium. Each pharmaceutical company has to fight in order to take an advantage of the first one who obtains patents. Moreover they are competing to bring their drugs to doctors' mind by hiring reps.

There are several alternatives to make a company less venerable. For the bargaining power of customers, in US, the MCOs are becoming stronger and stronger while the battle in prices against the purchaser outside the US is not decreasing so pharmaceutical companies cannot avoid reducing the prices of drugs. A pharmaceutical company can move its R&D centers to...

Strengths

1. Low cost of production.

2. Large pool of installed capacities

3. Efficient technologies for large number of Generics.

4. Large pool of skilled technical manpower.

5. Increasing liberalization of government policies.

Opportunities

1. Aging of the world population.

2. Growing incomes.

3. Growing attention for health.

4. New diagnoses and new social diseases.

5. Spreading prophylactic approaches.

6. Saturation point of market is far away.

7. New therapy approaches.

8. New delivery systems.

9. Spreading attitude for soft medication (OTC drugs).

10. Spreading use of Generic Drugs.

11. Globalization

12. Easier international trading.

13. New markets are opening.

Weakness

1. Fragmentation of installed capacities.

2. Low technology level of Capital Goods of this section.

3. Non-availability of major intermediaries for bulk drugs.

4. Lack of experience to exploit efficiently the new patent regime.

5. Very low key R&D.

6. Low share of India in World Pharmaceutical Production (1.2% of world production but having 16.1% of world''s population).

7. Very low level of Biotechnology in India and also for New Drug Discovery Systems.

8. Lack of experience in International Trade.

9. Low level of strategic planning for future and also for technology forecasting.

Threats

1. Containment of rising health-care cost.

2. High Cost of discovering new products and fewer discoveries.

3. Stricter registration procedures.

4. High entry cost in newer markets.

5. High cost of sales and marketing.

6. Competition, particularly from generic products.

7. More potential new drugs and more efficient therapies.

8. Switching over form process patent to product patent.

Pharmaceuticals & Healthcare Report India

Independent 5-year pharmaceutical and healthcare industry forecasts for India.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Indian pharmaceutical and healthcare industry.

Competitive intelligence, Indian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Indian market.

Show More
Related

  • CVS Marketing Development

    1503 Words  | 4 Pages

    There are very few alternatives to drugs. The alternatives are practically limited to traditional medicine. Therefore, the threat of substitute is weak.

    Read More

  • Designing a Global Strategy for Pharmaceutical Industry

    1279 Words  | 3 Pages

    The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals compounds for medical purpose. Pharmaceutical companies produce generic, brand medications and medical devices. The industry is subject to a complex regulatory environment regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs.

    Read More

  • Pharmaceutical Case Study

    1598 Words  | 4 Pages

    Stan Frinkelstein and Peter Temin believes that one solution is to eliminate the link between drug prices and drug discovery. This will help ease the fear of losing research funding for new medicine and by doing so, drug prices should be a lot more reasonable. The next solution they have is to undo the blockbuster mentality and this is closely linked to eliminating the link between drug prices and drug discovery. Blockbuster refers to pharmaceutical companies that achieve an annual worldwide sale of $1 billion or more. They can achieve this because the drugs are used by many patients and/or used for a long period of time. This will solve the drug price crisis because by doing so, researchers can focus more on society’s needs instead of focusing on how to generate more revenue. Their solutions will help researchers develop drugs that society truly

    Read More

  • MEDFIELD

    757 Words  | 2 Pages

    Pharmaceutical industry used to be a powerhouse industry with revenue of billions dollar. 1995 through 2002 was the hey-day period of pharmaceutical industry. In this period, profitability for the pharmaceutical companies was three times more than profitability of the median of all Fortune 500 companies in 2004.

    Read More

  • Drug Patents

    1902 Words  | 4 Pages

    Lehman, Bruce. 2003. “The Pharmaceutical Industry and the Patent System”. International Intellectual Property Institute. Pages 1-14.

    Read More

  • The War on Pharmaceutical Companies

    1185 Words  | 3 Pages

    In conclusion, pharmaceutical companies are extremely edacious and cold-blooded. Their profits numbers in the billion’s range while seniors are struggling to afford their prescribed drugs to survive. The pharmaceutical industry is strongly against Americans getting their prescriptions from Canada. Yet these people cannot help it; they are not financially secure to afford the drugs sold in America. The U.S. Government tries to isolate itself from the problem in order to make money from the taxes of prescriptions. However, almost every other country has some type of control over their pharmaceutical companies’ prices. In the future, with more and more drugs developed, only more and more money is going to be in need by the pharmaceutical industry. So unless something can be done soon, this war on drugs is only going to climb uphill. Yet how could these top-paid personnel understand what it feels like to be unable to afford prescription drugs in order to maintain a healthy body or even to stay alive? If there was an answer to that question, the dilemma of overpriced drugs might have a solution.

    Read More

  • Eli Lilly And Company: The Global Pharmaceutical Company

    1326 Words  | 3 Pages

    Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.

    Read More

  • The Power and Benefits of Monopolies in the Pharmaceutical Industry

    1993 Words  | 4 Pages

    Although monopolies appear damaging at times, there are arguments that they are an advantage to society. Monopolies in the pharmaceutical industry drive companies to pursue research and development (R&D) efforts to gain new patents. According to a 1992 study, among the 24 US. Industry groups, pharmaceuticals dedicated 16.6% of their amounts to basic research, while all other industries averaged at 5.3% (Sherer 1307). This fact validates the incentive pharmaceutical companies have to get a patent and acquire more power. Pfizer encourages R&D because of the incentives and a want to obtain patents to receive more profit. Pfizer has to promote itself to be successful, creating a good brand image that consumers will trust. If the company can advertise successfully, more consumers will purc...

    Read More

  • Case Analysis Of Merck & Co.

    1610 Words  | 4 Pages

    They are missing out on opportunities that exist externally. It is time for the mindset of the company to evolve and understand that not all great ideas will be developed internally. In order to jump back to being the leading pharmaceutical company, they will have to open their doors to external pharmaceutical innovation.

    Read More

  • Business Analysis of Teva Pharmaceuticals

    2720 Words  | 6 Pages

    Strengths: Teva had a strong customer base because of its presence in 50 countries globally and had acquired 14 very competent companies. The company had a reputation of world’s #1 generic drug company with substantial market share. The company’s portfolio was really strong with about 1300 molecules in generic drugs and had the patent of bloc...

    Read More

  • Business Analysis: Merck & Co.

    1393 Words  | 3 Pages

    10. Collis, David, and Troy Smith. "Strategy in the Twenty-First Century Pharmaceutical Industry:Merck&Co. and Pfizer Inc." Harvard Business School, 2007: 8-12.

    Read More

  • The Rise in the Price of Prescription Drugs

    1345 Words  | 3 Pages

    Why are the prices so high? Some critics of the drug companies argue that the larger firms are ripping off the American public, are dishonest and, in some cases, unsafe. On the other hand, there are health care workers such as doctors and their supporters who claim that research and testing for drugs costs money. This supposedly justifies their prices for their products. Also, as an argument to their side, they say that their practice is a benefit to the improvement to mankind. It is a life saving business, but are these prices justified? As one can see, this is a very important issue in medicine today. It affects everyone involved with medicine, which is much of the American public. It also affects the physicians and drug makers.

    Read More

  • A Strategic Analysis of Novartis

    1722 Words  | 4 Pages

    The original case was about Chiron, a biotechnology company, in the United States. Chiron was acquired in 2006 by Novartis, a Swedish company formed by the merger of Ciba-Geigy and Sandoz Laborites. Since Chiron itself no longer exists, we have focused our case around Novartis as of 2013. Novartis specializes in diagnostic services, generic and name brand medications, ophthalmological tools, as well as a small segment in pet health. The business prides itself in producing the latest drugs, hiring the best talent, and being a global leader in the pharmaceutical industry. Over the years the company has survived by focusing on its internal development in addition to a series of mergers, acquisitions, and corporate restructurings. Being a pharmaceutical company, the entire population is impacted: patients, physicians, employees, hospitals, and investors are some of the most important stakeholders.

    Read More

  • Supply Chain Management At Nicholas Piramal India

    1618 Words  | 4 Pages

    manpower and a large base of FDA approved plants, positions India high on the outsourcing

    Read More

  • Pros And Cons Of Patents In The Pharmaceutical Industry

    1477 Words  | 3 Pages

    Pharmaceutical patents are patents for inventions within the pharmaceutical industry. Patents give exclusive rights for an invention for a product or a process of making a product [1]. There are many aspects to patents in the pharmaceutical industry that are both pros and cons; it just depends on what industry you are in. Pharmaceutical companies take out patents so they can regulate the market and restrict competition from other companies. By obtaining patents pharmaceutical companies also attract investment. In addition to this pharmaceutical companies can also regulate the price of the drug as they will be the only company selling that drug. However these aspects of patents can adversely affect the generics industry. The generics industry cannot make or sell drugs that are patented but once a patent licence expires, both the generics industry and the WHO see increased benefits as drugs become more widely available around the world (i.e. developing countries) at a lower price. Here we will discuss the pros and cons of patents from the point of view of the pharmaceutical industry, generics industry and the WHO.

    Read More

More about Competition in Pharmaceuticals

Open Document